Erratum: WHO Grade IV Gliofibroma: A Grading Label Denoting Malignancy for an Otherwise Commonly Misinterpreted Neoplasm
Article information
To the Editor:
We found errors in our published article.
Escalante Abril PA, Salazar MF, López García NL, Madrazo Moya MN, Zamora Guerra YU, Mata Mendoza YG, Gómez Apo E, Chávez Macías LG. WHO grade IV gliofibroma: a grading label denoting malignancy for an otherwise commonly misinterpreted neoplasm. [Related article:] J Pathol Transl Med 2015; 49(4): 325-30. http://dx.doi.org/10.4132/jptm.2015.05.20
Page 328, Table 1.
The phrases “Mortality rate (cases with available data) (5/8)=62.5%” and “Overall mortality rate (cases with available data) (7/10) = 70.0%” of the Table 1 should read “Mortality rate (cases with available data) (3/8)=37.5%” and “Overall mortality rate (cases with available data) (5/10)=50.0%”, respectively.
Page 328, left column.
The sentence “However, when considering the lethality of the high-grade-only subset, this value increases to 70% or even 100% in cases with an accompanying glioblastoma component (Table 1).8-13” on page 328 should read “However, when considering the lethality in the sole high-grade subset, this value increases up to roughly 40% or even 100% in those instances with an accompanying glioblastoma component (Table 1).8-13”
Page 329, left column.
The sentence “As shown in our case and previously advised by other authors, gliofibroma prognosis is greatly influenced by the degree of anaplasia of the glial component” on page 329 should read “As shown in our case and previously advised by some authors, gliofibroma prognosis is, indeed, influenced by the degree of anaplasia of the glial component.”
We apologize for the inconvenience caused by these errors.